Rare Kidney Stone Consortium Biobank
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02026388|
Recruitment Status : Recruiting
First Posted : January 3, 2014
Last Update Posted : August 4, 2017
|Condition or disease|
|Primary Hyperoxaluria Dent Disease APRT Deficiency Cystinuria|
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Official Title:||Rare Kidney Stone Consortium Biobank, Rare Diseases Clinical Research Network|
|Study Start Date :||May 2013|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||June 2020|
Diagnosis of Primary Hyperoxaluria, or a family member of someone with this diagnosis.
Diagnosis of Dent Disease, or a family member of someone with this diagnosis.
Diagnosis of Cystinuria, or a family member of someone with this diagnosis.
Diagnosis of APRT Deficiency, or a family member of someone with this diagnosis.
- Number of samples stored in tissue bank [ Time Frame: 4 years ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02026388
|Contact: Alicia M Meekfirstname.lastname@example.org|
|Contact: Barbara M Seideemail@example.com|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Contact: Alicia M Meek 507-255-4347 firstname.lastname@example.org|
|Contact: Barbara M Seide 507-255-0387 email@example.com|
|Principal Investigator: Dawn S Milliner, M.D.|
|Principal Investigator:||Dawn S Milliner, M.D.||Mayo Clinic|